

# Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

*Petr Zatloukal, MD,\* Radj Gervais, MD,† Johan Vansteenkiste, MD, PhD,‡ Léon Bosquee, MD,§ Christiana Sessa, MD,|| Etienne Brain, MD, PhD,¶ Eric Dansin, MD,# Thierry Urban, MD, PhD,\*\* Nadine Dohollou, MD,†† Michèle Besenval, MD,‡‡ and Elisabeth Quoix, MD§§*

**Introduction:** This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of patients with nonirradiable stage IIIB or stage IV non-small cell lung cancer to select the combination having the most promising antitumor activity.

**Methods:** Patients received either larotaxel (50 mg/m<sup>2</sup>) as a 1-hour infusion, followed by a 1-hour infusion of cisplatin (75 mg/m<sup>2</sup>), every 3 weeks (arm A), or gemcitabine (800 mg/m<sup>2</sup>) as a 30 minute infusion, on days 1 and 8, and larotaxel (60 mg/m<sup>2</sup>) as a 1-hour infusion, on day 8 (following gemcitabine), every 3 weeks (arm B). The primary end point was the objective response rate (per-protocol population).

**Results:** Thirty-two patients were randomized to arm A and 30 to arm B. The response rate was higher in arm A compared with arm B in both the per-protocol (26.7% versus 18.2%) and intention-to-treat (28.1% versus 13.3%) populations. In the intention-to-treat population, median progression-free survival for arm A versus arm B was 4.7 versus 3.3 months and median overall survival was 8.6

versus 7.3 months, respectively. Fifty percent of patients in arm A and 66.7% in arm B experienced at least one National Cancer Institute common toxicity criteria grade 3/4 adverse event and grade 3/4 neutropenia was observed in 46.9% and 41.4% of patients, respectively.

**Conclusions:** Both larotaxel combinations were effective and manageable, however all measured efficacy parameters (response rate, progression free survival, and survival) seemed to favor the combination with cisplatin.

**Key Words:** Advanced NSCLC, Combination chemotherapy, First-line, Taxane, Larotaxel.

(*J Thorac Oncol.* 2008;3: 894–901)

Globally, lung cancer is the most frequently diagnosed malignancy and the disease remains the most common cause of cancer-related death.<sup>1</sup> The majority of tumors (~80%) are non-small cell lung cancers (NSCLCs).<sup>2</sup> As a consequence of the absence of effective, clinically-validated screening procedures, most NSCLCs are locally advanced or metastatic at presentation (stage IIIB and IV),<sup>3</sup> and therefore nonresectable. Treatment for advanced disease may comprise chemoradiotherapy (stage IIIB) or chemotherapy (stage IV).<sup>4</sup> Such essentially palliative treatment aims at controlling symptoms, improving quality of life, and lengthening survival.

A number of cytotoxic agents have been shown to be effective as first-line treatments for NSCLC. Currently, patients with good performance status will commonly receive a doublet comprising a platinum analogue (cisplatin or carboplatin) combined with a third-generation cytotoxic agent (gemcitabine, vinorelbine, or a taxane). Various combinations seem to be essentially equally effective,<sup>5,6</sup> with differences between regimens primarily limited to their side effect profiles.<sup>7,8</sup> Nonplatinum-based doublets, especially gemcitabine plus a taxane have been developed in an attempt to overcome cisplatin-associated toxicities. Results available at time of this study led to the recommendation by American Society of Clinical Oncology in 2003 of their use as an alternative to platinum-based doublets.<sup>4</sup>

\*Department of Pneumology and Thoracic Surgery, 3rd Faculty of Medicine, Charles University, Faculty Hospital Bulovka and Postgraduate Medical School, Praha, Czech Republic; †Centre François Baclesse, Caen, France; ‡Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium; §Service de pneumologie, Centre Hospitalier Universitaire, Sart-Tilman, Liège, Belgium; ||Ospedale San Giovanni, Bellinzona, Switzerland; ¶Department of Medical Oncology, Centre René Huguenin, Saint-Cloud, France; #Département de Cancérologie générale, Centre Oscar Lambret, Lille, France; \*\*Service de pneumologie, Centre Hospitalier Universitaire, Angers, France; ††Department of Medical Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; ‡‡Sanofi-Aventis, Antony, France; and §§Service de pneumologie, University Hospital, Strasbourg, France.

Disclosure: Michèle Besenval is employed by the organization. The other authors declare no conflict of interest.

Address for correspondence: Elisabeth Quoix, MD, Hôpital Lyautey, Service de Pneumologie, Hôpitaux Universitaires de Strasbourg, 1 Place de l'Hôpital, 67091 Strasbourg cedex, France. E-mail: elisabeth.quoix@chru-strasbourg.fr

Copyright © 2008 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/08/0308-0894

The taxanes, paclitaxel and docetaxel, are both effective and approved in combination with platinum in first-line NSCLC therapy.<sup>9</sup> Docetaxel is also approved as a single agent for second-line treatment. There is however a need to increase the effectiveness of such compounds in relation to increasing cytotoxicity in taxane-resistant tumors and decreasing systemic toxicity.<sup>10</sup> Larotaxel (XRP9881) is a novel semi-synthetic taxane compound that seems to be a potent microtubule stabilizer, blocking tubulin disassembly and thereby inhibiting mitosis. The drug efflux pump, P-glycoprotein 1 (encoded by the multidrug resistance gene, *ABCB1*), which is commonly overexpressed in tumors, may play a key role in taxane resistance. Larotaxel has a much lower affinity for P-glycoprotein 1 than docetaxel and was shown to be active in cell lines resistant to doxorubicin, vinblastine, paclitaxel, and docetaxel. In addition, this compound seems to cross the blood-brain barrier.<sup>11</sup>

Several phase I studies have explored different schedules of administration of larotaxel as a single agent and have recommended dose levels for phase II studies of 60 and 90 mg/m<sup>2</sup> for the every 3 weeks regimen.<sup>11–15</sup> Hematologic toxicity was the main dose-limiting toxicity in all the tested regimens. Other nonhematologic toxicities characteristically associated with taxanes, such as alopecia, gastrointestinal effects, neurosensory disorders, hypersensitivity reactions, skin disorders, and fluid retention were generally mild or moderate. Objective responses were observed in several tumor types. Of particular interest, Sessa and colleagues noted responses in three NSCLC patients. In one case, a response was seen in both the patient's primary tumor and also associated brain metastases.<sup>11</sup> This study provided a rational basis for the further testing of larotaxel in advanced NSCLC patients.

A preliminary three-arm phase I study investigated larotaxel in combination with cisplatin, gemcitabine, or vinorelbine. The recommended doses for the combination of larotaxel and cisplatin were 50 and 75 mg/m<sup>2</sup>, respectively and for larotaxel and gemcitabine; 60 and 800 mg/m<sup>2</sup>, respectively. However, larotaxel combined with vinorelbine showed poor tolerability, even at the lowest doses tested, and so this combination was rejected for phase II development (manuscript in preparation). Using response rate as the primary efficacy measure, the current phase II study was designed to investigate whether cisplatin or gemcitabine was the most appropriate partner for larotaxel in patients with chemotherapy naive advanced NSCLC.

## PATIENTS AND METHODS

### Major Eligibility Criteria

Chemotherapy naive patients were eligible for inclusion if they had histologically or cytologically-confirmed nonirradiable stage IIIB or stage IV NSCLC and were  $\geq 18$  and  $\leq 75$  years of age, with a life expectancy of at least 12 weeks and an Eastern Cooperative Oncology Group performance status of 0 to 2. They were not to have received surgery for NSCLC within the previous 4 weeks (excluding simple surgery for diagnosis or to implant a venous access device) and required adequate hematologic (neutrophils

$>2 \times 10^9/l$ , platelet count  $>100 \times 10^9/l$ ), renal (creatinine within upper normal limits or if borderline, with a creatinine clearance  $>60$  mL/min), and hepatic (total bilirubin within normal limits, serum aspartate aminotransferase/alanine aminotransferase and alkaline phosphatase  $\leq 2.5$  times the upper limits of normal or aspartate aminotransferase/alanine aminotransferase  $\leq 1.5$  times associated with alkaline phosphatase  $\leq 5$  times the upper limits of normal) function. Patients were required to have at least one measurable lesion according to response evaluation criteria in solid tumors criteria.<sup>16</sup> The study was conducted in accordance with the declaration of Helsinki and written informed patient consent was obtained before the implementation of any study-related procedures.

Main exclusion criteria were: a prior history of cancer (excluding basal cell skin or in situ disease); symptomatic brain or leptomeningeal metastases; hypercalcemia ( $>2.8$  mmol/l); peripheral neuropathy  $>$  grade 1; another serious comorbid condition; had received prior chemotherapy or radiotherapy (except for bone metastases) or were receiving another anticancer treatment or experimental drug.

### Study Design and Treatments

This was a multicenter, randomized study conducted in 11 centers in four countries (France, Belgium, Czech Republic and Switzerland). The primary objective was to select the combination having the most promising antitumor activity (response rate). Patients were randomly assigned centrally into two arms. Those in arm A received larotaxel (50 mg/m<sup>2</sup>) as a 1-hour infusion, followed after 30 minutes by a 1-hour infusion of cisplatin (75 mg/m<sup>2</sup>), every 3 weeks. Patients in arm B received gemcitabine (800 mg/m<sup>2</sup>) as a 30 minute infusion, on days 1 and 8, and larotaxel (60 mg/m<sup>2</sup>) as a 1-hour infusion, on day 8 (following gemcitabine, with no interval), every 3 weeks. Administration of larotaxel on day 8 in this arm was selected to match docetaxel/gemcitabine NSCLC schedules, which have been designed to avoid docetaxel-induced neutropenia (which generally occurs 5 to 8 days after administration) causing a delay in the day 8 administration of gemcitabine.<sup>17</sup> All patients in arm A received a setron (ondansetron or alternative) as a prophylactic antiemetic premedication from cycle 1. Patients in this arm were to be adequately hydrated to avoid the nephrotoxicity secondary to cisplatin administration. No prophylactic antiemetic drugs were allowed during the first cycle for patients in arm B. In subsequent cycles, in the case of nausea/vomiting, patients could receive preventive antiemetic treatment in compliance with the standard protocol of the center. Prophylaxis with dexamethasone was given (16 mg the day before, 24 mg the day of, and 16 mg the day after larotaxel administration).

Adverse events (AEs) were graded according to National Cancer Institute-Common Toxicity Criteria Version 2. In the event of long lasting AEs, the cycle could be extended for 1 week. No dose reduction was permitted for arm A and if such toxicity did not resolve by day 28, the patient was to discontinue the study treatment. For arm B, in the case of severe toxicity related to larotaxel or gemcitabine, a dose reduction to 50 and/or 650 mg/m<sup>2</sup>, respectively, was allowed.

The interval between day 1 of 2 consecutive cycles could be extended to 5 weeks for nondrug-related AEs, but only once during the study. Treatment was continued until disease progression, unacceptable toxicity, or the withdrawal of patient consent.

### Evaluations Before and During Therapy

Within 7 days before first study drug administration, medical history (including NSCLC histology/cytology, prior surgery other than for cancer, concurrent illness, prior medications, history of allergy) was recorded and a physical examination (height, weight, Eastern Cooperative Oncology Group performance status, vital signs) carried out. Standard hematologic and biochemical analyses and an evaluation of existing signs and symptoms were also completed. Within 4 weeks before treatment a cardiologic examination and radiologic scanning of the chest (x-ray or computed tomography; CT), abdomen (CT), brain (CT or magnetic resonance imaging) and when indicated, bone (scan or x-ray) were carried out, encompassing all target and nontarget (when indicated) lesions. During the study, a physical examination was carried out immediately before treatment, on day 1 of each cycle. Toxicity was evaluated weekly. Hematologic assessments were carried out every week, or every other day in the case of grade four neutropenia or thrombopenia (arm B) until recovery to grade  $\leq 3$  or  $< 3$ , respectively. Radiologic assessment of the chest and abdomen and all target and nontarget lesions was performed every 2 cycles (6 weeks) using the same method as the baseline evaluation.

### Statistical Methods and Considerations

The intention-to-treat (ITT) population comprised all randomized patients. The per-protocol population (PPP) was defined as a subset of the treated population: patients had to be eligible, evaluable for response, and without any major protocol deviations during the course of the study. The safety population was the treated population, defined as all patients who had been administered at least one (even incomplete) infusion of one study drug.

The primary objective was to rank the activity of the two test regimens using the Simon design.<sup>18</sup> An independent External Response Review Committee reviewed radiologic assessments to evaluate the best tumor response and to establish the date of progression (response evaluation criteria in solid tumors<sup>16</sup>). The primary efficacy variable was the objective response rate for the PPP, as assessed by the External Response Review Committee and as defined by the percentage of patients achieving a confirmed complete (CR) or partial (PR) response (CR + PR). Twenty-one patients/arm were to be included. Taking into account a likely rate of exclusion from the PPP of 10%, 23 patients/arm were to be enrolled. With this sample size, and assuming that the lowest response rate was 10%, there was a probability of 90% that the best treatment would be selected, provided that it was superior to the other by at least 15%.

Secondary efficacy variables included: duration of response (DR; defined as the time interval between meeting the criteria for a CR or PR and the date of the first documented progression or death from any cause), duration of stable

disease (SD) (defined as the time from randomization until disease progression or death for patients with SD as best overall response), progression-free survival (PFS; defined as the time from randomization until disease progression or death), and overall survival (OS; defined as the time from randomization until death). For DR and PFS evaluations, progression or death occurring 84 days or more after the last evaluable tumor assessment was censored back to the date of that assessment. OS was censored at the date of last contact or the cutoff date, whichever came first.

Categorical variables were summarized by frequency and percentage. Ninety five percent confidence intervals [95%] were calculated using the Clopper–Pearson exact method,<sup>19</sup> where appropriate. Continuous variables were presented with summary statistics (mean, standard deviation, median, range). Kaplan–Meier curves<sup>20</sup> and estimates<sup>21</sup> (median and its 95% confidence interval) were used to analyze variables of duration and event.

## RESULTS

### Patient Demographics

Sixty-two patients were randomized between 30th July 2002 and 17th June 2003: 32 to arm A (larotaxel/cisplatin) and 30 to arm B (larotaxel/gemcitabine). Patient characteristics at baseline were generally well balanced between the arms, except gender (Table 1). Similarly, baseline tumor characteristics were well balanced with only slight differences in the interarm frequencies of the number and type of organs involved and stage of disease at first diagnosis (Table 1). The majority of patients had stage IV disease, with adenocarcinoma being the most common histologic class. Most patients had three or more organs affected.

### Treatment Administration

Thirty-two patients in arm A received a total of 127 cycles (median 4, range 1–8) and 30 patients in arm B received a total 116 cycles (median 4, range 1–6). Table 2 summarizes drug exposure. Reflecting the absence of protocol-permitted dose reduction in arm A, the relative dose intensity was 0.98 for both larotaxel and cisplatin. In arm B, 28 of 30 patients received larotaxel, with 2 discontinuing treatment immediately after the first gemcitabine infusion (day 1) following, in 1 case, grade 4 supraventricular arrhythmia and in 1 case, pulmonary embolism (neither considered related to study treatment). The relative dose intensity in this arm for larotaxel was 0.94 and for gemcitabine was 0.93, with these intensities demonstrating the feasibility of the combination. Although not allowed, 1 (3.1%) patient (1 cycle, 0.8%) in arm A did have a dose reduction (larotaxel; cycle 3) following anemia. In arm B, 7 (23.3%) patients experienced a dose reduction in 9 cycles (7.8%), due to hematologic toxicity for two patients, nonhematologic toxicity for three patients (diarrhea, nausea, and vomiting); for the two remaining patients no specific reason was given. Among the 9 cycles with dose reduction, larotaxel was reduced in eight and gemcitabine in one. Eleven patients (34.4%) in arm A and 13 patients (43.3%) in arm B had a delay in at least 1 cycle. A total of 16 (12.6%) cycles were delayed in arm A and 22



**TABLE 1.** Patient and Disease Characteristics at Baseline

Characteristic	Arm A (N = 32)	Arm B (N = 30)	All Patients (N = 62)
Gender, n (%)			
Male	21 (65.6)	26 (86.7)	47 (75.8)
Female	11 (34.4)	4 (13.3)	15 (24.2)
Race, n (%)			
Caucasian	32 (100.0)	30 (100.0)	62 (100.0)
Age, yr			
Median (range)	57 (43–75)	62 (40–72)	60 (40–75)
<65 yr, n (%)	21 (65.6)	22 (73.3)	43 (69.4)
≥65 yr, n (%)	11 (34.4)	8 (26.7)	19 (30.6)
PS before first infusion, n (%)			
Median (range)	1 (0–2)	1 (0–2)	1 (0–2)
0	9 (28.1)	7 (23.3)	16 (25.8)
1	20 (62.5)	19 (63.3)	39 (62.9)
2	3 (9.4)	4 (13.3)	7 (11.3)
Signs and symptoms at baseline, n (%)	27 (84.4)	28 (93.3)	55 (88.7)
Histology type, n (%)			
Adenocarcinoma	17 (53.1)	15 (50.0)	32 (51.6)
Large cell carcinoma	2 (6.3)	4 (13.3)	6 (9.7)
NSCLC undetermined	2 (6.3)	—	2 (3.2)
Squamous cell carcinoma	11 (34.4)	11 (36.7)	22 (35.5)
Stage of disease at baseline			
IIIB	5 (15.6)	5 (16.7)	10 (16.1)
IV	27 (84.4)	25 (83.3)	52 (83.9)
Measurable disease, n (%)	32 (100.0)	30 (100.0)	62 (100.0)
Number of organs involved			
1	1 (3.1)	4 (13.3)	5 (8.1)
2	12 (37.5)	6 (20.0)	18 (29.0)
3	13 (40.6)	15 (50.0)	28 (45.2)
4 or more	6 (18.8)	5 (16.7)	11 (17.7)
Organ involvement, n (%)			
Lung	30 (93.8)	24 (80.0)	54 (87.1)
Soft tissue (lymph nodes)	27 (84.4)	22 (73.3)	49 (79.0)
Brain	4 (12.5)	6 (20.0)	10 (16.1)
Bone	9 (28.1)	5 (16.7)	14 (22.6)
Adrenal gland	6 (18.8)	8 (26.7)	14 (22.6)
Liver	5 (15.6)	7 (23.3)	12 (19.4)
Pleura	5 (15.6)	6 (20.0)	11 (17.7)

Arm A, larotaxel + cisplatin; Arm B, larotaxel + gemcitabine; PS, performance status; NSCLC, non-small cell lung cancer.

(19.0%) in arm B. The most common reasons for cycle delays were other reason (administrative reasons) in arm A and hematologic toxicity in arm B. All patients had discontinued treatment by the cutoff date of 15th May 2005, with the most common reason in both arms being progressive disease, followed by no further benefit expected and adverse event.

### Efficacy

Primary and secondary efficacy data are detailed in Table 3. There were no CR. Response rates in the PPP for arm A and arm B were 26.7% and 18.2% and for the ITT population 28.1% and 13.3%, respectively. In addition, 40.0% and 36.4% (PPP), 40.6% and 33.3% (ITT) of patients

respectively had SD. In brain lesions (10 patients), no objective responses were observed but stabilization was achieved in three of four patients in arm A and one of six in arm B.

As only 13 patients (including six censored in arm A and two in arm B) had an objective response, Kaplan–Meier plots for DR were not constructed. The DR ranged between 1.45+ and 20.63+ months. Median PFS was similar in arm A of the PPP compared with arm B (4.3 versus 4.4 months) but a difference of 1.4 months was observed in the ITT population (4.7 versus 3.3 months, respectively). In arm B, two out of four patients with very short PFS were excluded from the PPP (baseline tumor assessment done more than 31 days before first infusion) and probably explain the difference in PFS between ITT and PPP. In the ITT population, median OS was 8.6 months in arm A and 7.3 months in arm B (Figure 1) and the 1-year survival rate was 40.6% in arm A and 30.0% in arm B.

### Safety

Eight (25.0%) patients in arm A and nine (30.0%) patients in arm B experienced grade 3/4 treatment emergent adverse events related to study treatment (Table 4). The highest incidences of such events (nonhematological) were infection (9.4%) and vomiting (6.3%) in arm A, and infection (10.0%), diarrhea and allergic reaction (6.7%) in arm B. Of note, a similar rate of patients experienced grade 3/4 infection related to study treatment. However, more patients experienced grade 3/4 infection regardless of relationship to study treatment (with or without neutropenia) in arm B compared with arm A (12.5% in arm A; 26.7% in arm B). Given that the excess of infection cases in arm B seemed not to be related to treatment, that the patients were randomized to the study arms and that there were no obvious imbalances in patient/disease characteristics at baseline that might explain this excess, this is most likely a chance finding.

Neutropenia was the most common grade 3/4 hematologic toxicity in both arms (arm A: 46.9%, arm B: 41.4%), with grade 3/4 thrombocytopenia reported for only one patient (3.4%) in arm B. Two (6.3%) patients experienced febrile neutropenia in arm A (no patients in arm B), and three (10.0%) patients experienced neutropenic infection in each arm.

The incidence of peripheral neurotoxicity was similar in both arms (arm A: 18.8%, arm B: 20.0%) with no patients experiencing grade 3. More any grade creatinine increase was noted for arm A compared with arm B (37.5% versus 10%). However, this was grade 1 in all but two (6.3%) patients (grade 2, which subsequently improved to grade 1).

One patient in arm A (3.1%) and four patients in arm B (13.3%) died within 30 days of the last treatment administration (Table 5). Two of the deaths in arm B (6.7%) were considered to be related to study treatment: one patient died of infection (with concomitant grade 3/4 neutropenia) on day 11 of the last infusion at cycle 2, and another died of infection (with concomitant grade 3/4 neutropenia) on day 7 of the last infusion at cycle 1.

**TABLE 2.** Exposure to Treatment


Exposure	Arm A		Arm B	
	Larotaxel	Cisplatin	Larotaxel	Gemcitabine
No. of treated patients	32	32	28	30
Cumulative dose, (mg/m <sup>2</sup> )				
Median (range)	200.9 (49.3–397.9)	301.4 (73.9–588.4)	238.0 (59.5–364.9)	6373.3 (767.1–9731.8)
Actual dose intensity, (mg/m <sup>2</sup> /wk)				
Median (range)	16.3 (14.3–17.4)	24.5 (21.3–25.7)	18.9 (10.9–20.2)	498.3 (255.7–539.9)
Relative dose intensity				
Median (range)	0.98 (0.86–1.04)	0.98 (0.85–1.03)	0.94 (0.54–1.01)	0.93 (0.48–1.01)

**TABLE 3.** Primary and Secondary Efficacy Data in the Per-Protocol and ITT Populations

Parameter	PPP		ITT	
	Arm A (N = 30)	Arm B (N = 22)	Arm A (N = 32)	Arm B (N = 30)
Response, n (%)				
Complete response (CR)	—	—	—	—
Partial response (PR)	8 (26.7)	4 (18.2)	9 (28.1)	4 (13.3)
No change/stable disease	12 (40.0)	8 (36.4)	13 (40.6)	10 (33.3)
Progressive disease	8 (26.7)	9 (40.9)	8 (25.0)	10 (33.3)
Not evaluable	2 (6.7)	1 (4.5)	2 (6.3)	6 (20)
Overall response rate (CR + PR)	8 <sup>a</sup> (26.7)	4 (18.2)	9 (28.1)	4 (13.3)
[95% CI]	[12.3, 45.9]	[5.2, 40.3]	[13.7, 46.7]	[3.8, 30.7]
Median PFS (mo)	4.3	4.4	4.7	3.3
[95% CI]	[2.76, 4.96]	[1.54, 6.08]	[2.92, 6.21]	[1.45, 5.42]
Median overall survival (mo)	ND	ND	8.6	7.3
[95% CI]			[5.39, 16.03]	[4.76, 11.07]
1-yr survival (mo)			40.6%	30.0%

<sup>a</sup> One patient achieving a response was ineligible for inclusion in the PPP population as a consequence of major protocol deviations at study entry (baseline tumor assessment more than 31 d prior to first infusion and previous radiotherapy).

PPP, per-protocol population; ITT, intention to treat population; Arm A, larotaxel + cisplatin; Arm B, larotaxel + gemcitabine; PFS, progression-free survival; ND, not determined; CI, confidence interval.



**FIGURE 1.** Kaplan–Meier curve for overall survival in the ITT population.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.